FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

Prothena Adds Ex-FDA Neuroscience Head to Board

Prothena says it has appointed former CDER Office of Neuroscience director Billy Dunn to its board of directors.

latest-news-card-1
FDA General

Attorney Sues FDA to Keep Name Off FDA-483

An attorney who works for a company regulated by FDA asks the DC federal court to stop the agency from publishing the attorneys name and identifying i...

latest-news-card-1
Human Drugs

Pharmedica CGMP Violations Result in Plant Shutdown

Phoenix, AZ-based Pharmedica USA tells FDA it will stop all drug production and distribution after the agency finds CGMP violations during an inspecti...

latest-news-card-1
Federal Register

Tack Endovascular Device Regulatory Review Period

Federal Register notice: FDA determines for patent term extension purposes the regulatory review period for Intact Vasculars Tack Endovascular System....

latest-news-card-1
Human Drugs

Ipca Laboratories FDA-483

FDA releases the form FDA-483 with three observations issued following an April inspection at the Ipca Laboratories drug manufacturing facility in Hav...

latest-news-card-1
Medical Devices

FDA Issues with Sea-Long Medical Treatment Hoods

FDA warns Waxahachie, TX-based Sea-Long Medical Systems about multiple Quality System regulation violations in its production of misbranded and adulte...

latest-news-card-1
Human Drugs

Bespoke Gene Therapy Portfolio has 8 Diseases

The Bespoke Gene Therapy Consortium, of which FDA is a member, chooses eight rare diseases for a clinical trial portfolio intended to speed the develo...

latest-news-card-1
Human Drugs

Let Compounders Help with Drug Shortages: Op-Ed

The Alliance for Pharmacy Compounding calls for changes to federal law to allow compounding pharmacies to help address temporary drug shortages under ...

latest-news-card-1
Human Drugs

Did Recarbrio Approval Break FDA Rules?

A BMJ investigation questions how FDA approved Mercks antibiotic Recarbrio in 2019 since it did not appear to meet agency requirements for substantial...

latest-news-card-1
Federal Register

Regulatory Review Period for Ciplas Zemdri

Federal Register notice: FDA determines for patent term extension purposes the regulatory review period for Cipla USAs Zemdri (plazomicin).